Miramar Capital’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $22.3M | Sell |
102,582
-2,423
| -2% | -$537K | 4.97% | 2 |
|
|
2025
Q4 | $24M | Sell |
105,005
-1,421
| -1% | -$324K | 5.24% | 4 |
|
|
2025
Q3 | $24.6M | Sell |
106,426
-1,348
| -1% | -$275K | 5.47% | 3 |
|
|
2025
Q2 | $20M | Buy |
107,774
+2,106
| +2% | +$391K | 4.73% | 3 |
|
|
2025
Q1 | $22.1M | Sell |
105,668
-3,461
| -3% | -$673K | 5.27% | 1 |
|
|
2024
Q4 | $19.4M | Buy |
109,129
+7,348
| +7% | +$1.35M | 4.63% | 4 |
|
|
2024
Q3 | $20.1M | Sell |
101,781
-1,060
| -1% | -$198K | 4.69% | 2 |
|
|
2024
Q2 | $17.6M | Buy |
102,841
+764
| +0.7% | +$127K | 4.41% | 4 |
|
|
2024
Q1 | $16.6M | Sell |
102,077
-1,220
| -1% | -$210K | 4.19% | 4 |
|
|
2023
Q4 | $16M | Sell |
103,297
-5,814
| -5% | -$848K | 4.17% | 5 |
|
|
2023
Q3 | $16.3M | Sell |
109,111
-4,174
| -4% | -$613K | 4.42% | 4 |
|
|
2023
Q2 | $15.3M | Sell |
113,285
-1,006
| -0.9% | -$148K | 3.87% | 6 |
|
|
2023
Q1 | $18.2M | Buy |
114,291
+784
| +0.7% | +$120K | 4.68% | 1 |
|
|
2022
Q4 | $18.3M | Buy |
113,507
+14
| +0% | +$2.15K | 4.81% | 1 |
|
|
2022
Q3 | $16.8M | Buy |
113,493
+5,462
| +5% | +$784K | 4.61% | 1 |
|
|
2022
Q2 | $16.5M | Buy |
108,031
+3,858
| +4% | +$590K | 4.68% | 1 |
|
|
2022
Q1 | $16.9M | Buy |
104,173
+13,003
| +14% | +$1.89M | 4.63% | 1 |
|
|
2021
Q4 | $12.3M | Buy |
91,170
+2,513
| +3% | +$297K | 4.19% | 4 |
|
|
2021
Q3 | $9.56M | Buy |
88,657
+5,436
| +7% | +$621K | 3.81% | 4 |
|
|
2021
Q2 | $9.58M | Buy |
83,221
+1,570
| +2% | +$177K | 3.87% | 4 |
|
|
2021
Q1 | $8.84M | Sell |
81,651
-444
| -0.5% | -$47.5K | 3.95% | 2 |
|
|
2020
Q4 | $8.77M | Buy |
82,095
+16,952
| +26% | +$1.63M | 3.91% | 3 |
|
|
2020
Q3 | $5.75M | Buy |
65,143
+1,045
| +2% | +$98.4K | 3.34% | 12 |
|
|
2020
Q2 | $6.04M | Buy |
64,098
+2,133
| +3% | +$188K | 3.73% | 10 |
|
|
2020
Q1 | $4.72M | Buy |
61,965
+1,230
| +2% | +$105K | 4.3% | 7 |
|
|
2019
Q4 | $5.12M | Buy |
60,735
+5,550
| +10% | +$461K | 3.14% | 15 |
|
|
2019
Q3 | $4.27M | Buy |
55,185
+1,192
| +2% | +$81.7K | 2.88% | 19 |
|
|
2019
Q2 | $3.6M | Buy |
53,993
+13,023
| +32% | +$1.02M | 2.55% | 21 |
|
|
2019
Q1 | $3.3M | Buy |
40,970
+95
| +0.2% | +$7.77K | 2.53% | 21 |
|
|
2018
Q4 | $3.27M | Buy |
+40,875
| New | +$3.59M | 2.56% | 23 |
|
Other funds holding ABBV
VCM
VPM
Miramar Capital's ABBV Position: Q1 2026 in Review
Miramar Capital reduced its AbbVie (ABBV) stake by 2.3% in Q1 2026, selling an estimated $537K and leaving 102,582 shares worth $22.3M. The position accounts for 4.97% of the portfolio, ranked #2.
Miramar Capital first reported a position in ABBV in Q4 2018 and has held it in 30 quarters since. The position peaked at $24.6M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Miramar Capital held 102,582 shares of AbbVie worth $22.3M as of Q1 2026.
- Miramar Capital sold 2,423 AbbVie shares in Q1 2026, an estimated $537K.
- AbbVie made up 4.97% of Miramar Capital's portfolio in Q1 2026, its #2 holding.
- Miramar Capital first reported a position in AbbVie in Q4 2018 and has held it in 30 quarters since.
- Miramar Capital's AbbVie position peaked at $24.6M in Q3 2025.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Miramar Capital's 13F filing for Q1 2026, filed 11 May 2026.